Literature DB >> 30759019

Mitochondrial Dysfunction as a Pathogenic Mediator of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.

Stefan W Ryter1, Ivan O Rosas2, Caroline A Owen2, Fernando J Martinez1, Mary E Choi3, Chun Geun Lee4,5, Jack A Elias4,5, Augustine M K Choi1.   

Abstract

The mechanisms underlying the pathogenesis of chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis, remain incompletely understood. Mitochondria are vital cellular organelles crucial for energy generation, the maintenance of cellular metabolism, calcium homeostasis, intracellular signaling, and the regulation of cell death programs. Emerging evidence suggests that mitochondrial dysfunction plays a cardinal role in the initiation and progression of many human diseases, including chronic lung diseases. Upregulation of the autophagy program, a cellular adaptive mechanism for protein and organelle turnover, can occur in response to injury and may have a cell type-specific impact on the progression of disease. The selective autophagy subtype specific for mitochondria (mitophagy), regulated by PINK1 (phosphatase and tensin homolog-induced putative kinase 1), is a cellular response to accumulation of depolarized or injured mitochondria. Autophagy and mitophagy may be associated with either cellular protection or propagation of injury in a cell type-specific manner, and they may also be associated with modulation of cell death pathways. Genetic studies in mouse models have revealed opposing roles for PINK1 and/or mitophagy in the propagation of emphysema and fibrosis, whereas human studies have shown altered regulation of PINK1 in both idiopathic pulmonary fibrosis and COPD. We have also recently identified a role for mitophagy in regulating the cellular necroptosis program, with implications in COPD pathogenesis. Damage-associated molecular patterns released from injured mitochondria and/or necrotic cells may promote proinflammatory and profibrotic responses. In this review, we explore current experimental evidence for mitochondrial dysfunction as a key determinant in the pathogenesis of chronic lung diseases.

Entities:  

Keywords:  autophagy; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; mitochondrial dysfunction; mitophagy

Mesh:

Substances:

Year:  2018        PMID: 30759019     DOI: 10.1513/AnnalsATS.201808-585MG

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  26 in total

Review 1.  Mitochondrial biology in airway pathogenesis and the role of NRF2.

Authors:  Hye-Youn Cho; Steven R Kleeberger
Journal:  Arch Pharm Res       Date:  2019-09-04       Impact factor: 4.946

2.  Quantification of mitochondrial membrane potential in the isolated rat lung using rhodamine 6G.

Authors:  Said H Audi; Anthony Cammarata; Anne V Clough; Ranjan K Dash; Elizabeth R Jacobs
Journal:  J Appl Physiol (1985)       Date:  2020-03-05

Review 3.  Clinical and Molecular Delineation of Cutis Laxa Syndromes: Paradigms for Homeostasis.

Authors:  Aude Beyens; Lore Pottie; Patrick Sips; Bert Callewaert
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Alveolar macrophages in early stage COPD show functional deviations with properties of impaired immune activation.

Authors:  Kevin Baßler; Wataru Fujii; Theodore S Kapellos; Erika Dudkin; Nico Reusch; Ari Horne; Benedikt Reiz; Malte D Luecken; Collins Osei-Sarpong; Stefanie Warnat-Herresthal; Lorenzo Bonaguro; Jonas Schulte-Schrepping; Allon Wagner; Patrick Günther; Carmen Pizarro; Tina Schreiber; Rainer Knoll; Lisa Holsten; Charlotte Kröger; Elena De Domenico; Matthias Becker; Kristian Händler; Christian T Wohnhaas; Florian Baumgartner; Meike Köhler; Heidi Theis; Michael Kraut; Marc H Wadsworth; Travis K Hughes; Humberto J Ferreira; Emily Hinkley; Ines H Kaltheuner; Matthias Geyer; Christoph Thiele; Alex K Shalek; Andreas Feißt; Daniel Thomas; Henning Dickten; Marc Beyer; Patrick Baum; Nir Yosef; Anna C Aschenbrenner; Thomas Ulas; Jan Hasenauer; Fabian J Theis; Dirk Skowasch; Joachim L Schultze
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

5.  Acquisition of cellular properties during alveolar formation requires differential activity and distribution of mitochondria.

Authors:  Kuan Zhang; Erica Yao; Biao Chen; Ethan Chuang; Julia Wong; Robert I Seed; Stephen L Nishimura; Paul J Wolters; Pao-Tien Chuang
Journal:  Elife       Date:  2022-04-06       Impact factor: 8.713

Review 6.  Recent progress in the use of mitochondrial membrane permeability transition pore in mitochondrial dysfunction-related disease therapies.

Authors:  Yuting Cui; Mingyue Pan; Jing Ma; Xinhua Song; Weiling Cao; Peng Zhang
Journal:  Mol Cell Biochem       Date:  2020-09-30       Impact factor: 3.396

7.  Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin.

Authors:  Chongxu Zhang; Renzhi Cai; Aaron Lazerson; Gaetan Delcroix; Medhi Wangpaichitr; Mehdi Mirsaeidi; Anthony J Griswold; Andrew V Schally; Robert M Jackson
Journal:  Lung       Date:  2019-08-07       Impact factor: 2.584

8.  Age-dependent assessment of genes involved in cellular senescence, telomere and mitochondrial pathways in human lung tissue of smokers, COPD and IPF: Associations with SARS-CoV-2 COVID-19 ACE2-TMPRSS2-Furin-DPP4 axis.

Authors:  Krishna P Maremanda; Isaac K Sundar; Dongmei Li; Irfan Rahman
Journal:  Res Sq       Date:  2020-06-15

Review 9.  Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis.

Authors:  Marta Bueno; Jazmin Calyeca; Mauricio Rojas; Ana L Mora
Journal:  Redox Biol       Date:  2020-03-19       Impact factor: 11.799

10.  Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke.

Authors:  De-Qing Yang; Qiu-Nan Zuo; Tao Wang; Dan Xu; Liu Lian; Li-Juan Gao; Chun Wan; Lei Chen; Fu-Qiang Wen; Yong-Chun Shen
Journal:  Oxid Med Cell Longev       Date:  2021-06-15       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.